HONG KONG – South Korea's biopharmaceutical venture Genome & Co. Ltd. recently secured KRW30.2 billion (US$25.2 million) in series C investment with an IPO and global clinical trial plans for next year.
BEIJING – Cancer and autoimmune specialist Innocare Pharma Ltd., of Beijing, is seeking a pre-revenue listing on the Hong Kong Stock Exchange (HKEX) to raise capital to advance its BTK inhibitor, ICP-022, to an NDA filing in China by the end of this year.
CEO Christine Bunt of Verseau Therapeutics Inc. told BioWorld that the company has prepared a "wave" of prospects from its macrophage checkpoint modulator (MCM) platform ready to crash upon the shores of cancer therapy, with 23 novel targets in the hopper.
It took Kandaswamy (Swamy) Vijayan, CEO of newly launched Plexium Inc., a few years to figure out where he needed to focus his creative energies. With an engineering background, he helped develop diagnostic tools. But he wanted to take the skill further. "For longest time, I thought diagnostics were the be all and end all," Vijayan told BioWorld MedTech.
DUBLIN – Sofinnova Partners closed its ninth early stage venture capital fund, Sofinnova Capital IX, at €333 million (US$369 million) and is bringing the same playbook to bear on current investment opportunities that it has followed in the recent past.
RSS